Rituximab Combined With MSCs in the Treatment of PNS (3-4 Stage of CKD)
Status:
Unknown status
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
Primary nephrotic syndrome(PNS) is a group of clinical symptoms caused by a variety of
factors, including immune,environmental, genetic, et al. Oral corticosteroids have been to be
the preferred drug for the treatment of PNS, but the long-term use of glucocorticoid therapy
in clinic often induces some problems such as hormone dependent and hormone resistance, as
well as severe side effects which act as a threat to the patients' health. Besides, patients
with proteinuria long-term not control often behave faster progression into chronic renal
failure, leading to poor prognosis. In renal diseases, Rituximab ( RTX) is often used in the
treatment of refractory nephropathy, such as hormone dependent nephrotic syndrome, hormone
resistance nephrotic syndrome, frequency recurrence nephrotic syndrome, which shows exciting
effects in delaying the development of the disease.At present, mesenchymal stem cells ( MSCs)
has been used as a research hotspot to repair the tissue damage of chronic kidney disease,
and it also behaves certain effects. The purpose of this study is to seek a more targeted
treatment, more precise curative effect and more feasibility treatment for PNS(CKD3-4),so as
to delay or reverse the disease and improve the quality of life of patients with CKD.